Sample	Days from diagnosis	Tissue	Gender	Age	Blast count	RHP Mutations	Cytogenetics	Common translocation	Remarks	Cell number	UMIs min	UMIs mean	UMIs max	Genes min	Genes mean	Genes max
BM1	NA	Bone marrow	M	52	NA	NA	Unknown	NA		108	1069	3018	13186	503	1005	3306
BM2	NA	Bone marrow	M	21	NA	NA	Unknown	NA		188	1180	3908	19653	503	1129	3430
BM3	NA	Bone marrow	M	56	NA	NA	Unknown	NA		643	1007	3093	26834	500	1087	5023
BM4	NA	Bone marrow	M	23	NA	NA	Unknown	NA		3738	1000	4059	39196	500	1346	6744
BM5 CD34+	NA	Bone marrow	M	45	NA	NA	Unknown	NA	Not cryopreserved.	1431	1000	2822	16225	500	1048	3497
BM5 CD34+CD38-	NA	Bone marrow	M	45	NA	NA	Unknown	NA	Not cryopreserved. These cells were downsampled for clustering in Figure 1 (see Methods).	1590	1005	2558	11932	501	967	2737
AML1012	D0	Bone marrow	F	32	65 %	KRAS NM_004985 c.38G>A p.G13D (4.6%) /// NRAS NM_002524 c.38G>A p.G13D (39.0%) /// NOTCH2 NM_024408 c.4238T>A p.L1413H (50.8%, VUS) /// SF3A1 NM_005877 c.1432G>A p.G478S (44.2%, VUS)	46,XX,inv(16)(p13q22)[4]/48,idem,+8,+21[16]	CBFB-MYH11	Newly diagnosed AML, pre-treatment.	1136	1002	2308	14065	501	939	3370
AML210A	D0	Bone marrow	M	67	83 %	DNMT3A NM_175629 c.2644C>T p.R882C (43.4%) /// NPM1 NM_002520 c.859_860insTCTG p.W288fs*>9 (42.7%) /// TET2 NM_001127208 c.1072A>G p.S358G (49.3%, VUS) /// FLT3-ITD NM_004119 c.1802_1802insTTGAATATGATCTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTG	46,XY[20]	NA	Newly diagnosed AML with myelomonocytic differentiation, pre-treatment.	748	1001	2684	20440	500	997	4097
AML419A	D0	Bone marrow	F	54	60 %	CEBPA NM_004364 c.118_118insC p.P39fs* (42.9%) /// DNMT3A NM_175629 c.2644C>T p.R882C (41.9%) /// NPM1 NM_002520 c.859_860insTCTG p.W288fs*>9 (37.9%) /// FLT3 NM_004119 c.2039C>T p.A680V (29.0%) /// FLT3 NM_004119 c.2523C>A p.N841K (16.2%) /// FLT3-ITD NM_004119 c.1819_1819insTATGATCTCAAATGGGAGTTTCCA (13.5%) /// JAK3 NM_000215 c.2773C>A p.R925S (55.1%, VUS) 	46,XX[20]	NA	Newly diagnosed AML with monocytic differentiation, pre-treatment.	1189	1001	2965	28543	501	1181	5709
AML916	D0	Bone marrow	F	57	75 %	TP53 NM_000546 c.713G>A p.C238Y (97.6%)	"46,XX[20]
"	NA	Mixed phenotype acute leukemia expressing markers of stem cells (CD34, CD117), myeloid (CD64), T (CD3) and B (CD19) lineages by flow, pre-treatment.	933	1000	2179	9348	518	1022	3072
AML921A	D0	Bone marrow	M	42	70 %	DNMT3A NM_175629 c.2645G>A p.R882H (44.2%) /// RUNX1 NM_001754 c.167T>C p.L56S (63.5%, VUS) /// SETD2 NM_014159 c.3229A>G p.T1077A (48.4%, VUS)	46,XY	NA	Newly diagnosed AML, pre-treatment.	3813	1002	2948	27055	501	1186	5336
AML314	D0	Bone marrow	M	54	28 %	BCOR NM_001123385 c.2098delG p.K699fs* (36.4%) /// RUNX1 NM_001754 c.966_967delTC p.S322fs*160 (17.2%)	46,XY	NA	Newly diagnosed AML NOS, pre-treatment.	162	1003	1948	6923	501	786	2018
AML314	D31	Bone marrow	M	54	1 %	Not performed	46,XY[20]	NA	Morphologic remision, post-induction chemotherapy.	346	1003	3213	23606	501	1094	4211
AML371	D0	Bone marrow	M	51	16 %	NRAS NM_002524 c.181C>A p.Q61K (37.9%) /// WT1 NM_024426 c.1130_1130insGTAGCCCCGA p.T309fs*11 (13.3%)	"46,XY,der(16)t(16;18)(p1?2;p11.3)del(16)(q22q24),der(18)t(16;18)(p12;p11.3)[20].ish der(16)(18pter+,5'CBFB+),der(18)(pter-)"	NA	Newly diagnosed AML with monocytic differentiation, pre-treatment.	756	1001	2452	17127	503	997	3376
AML371	D34	Bone marrow	M	51	1 %	None Detected	46,XY	NA	Morphologic remision, post-induction chemotherapy.	204	1001	2447	11518	500	989	2933
AML475	D0	Bone marrow	M	70	1% (76% promono-cytes)	DNMT3A NM_175629 c.2645G>A p.R882H (43.9%) /// BCOR NM_001123385 c.2926C>T p.R976* (83.0%) /// BCORL1 NM_021946 c.1942_1943insC p.T648fs* (13.3%) /// BCORL1 NM_021946 c.2996delC p.T999fs* (8.2%) /// BCORL1 NM_021946 c.3142C>T p.R1048* (50.0%) /// BCORL1 NM_021946 c.3586C>T p.R1196* (4.1%)	46,XY	NA	Newly diagnosed AML with monocytic differentiation, pre-treatment.	423	1014	2757	10776	500	953	2624
AML475	D29	Bone marrow	M	70	1 %	Not performed	46,XY[20]	NA	Morphologic remission, post-induction chemotherapy.	102	1122	7556	99612	504	1421	4793
AML722B	D0	Bone marrow	F	52	84 %	BCORL1 NM_021946 c.1627delG p.D542fs* (7.2%) /// IDH2 NM_002168 c.515G>A p.R172K (42.3%) /// ASXL1 NM_015338 c.1231C>T p.R411C (45.3%, VUS) /// PHF6 NM_001015877 c.976T>C p.Y325H (38.2%, VUS) /// PTPN11 NM_002834 c.893A>G p.N298S (51.2%, VUS)	"46,XX,i(7)(p10) or add(7)(q11.2)[17]/47,XX,+8[3]
"	NA	Newly diagnosed AML, pre-treatment.	79	1069	2377	6818	500	811	1964
AML722B	D49	Bone marrow	F	52	3 %	IDH2 NM_002168 c.515G>A p.R172K (0.5%) /// ASXL1 NM_015338 c.1231C>T p.R411C (46.7%, VUS) /// PTPN11 NM_002834 c.893A>G p.N298S (47.4%, VUS)	Unknown	NA	Post 7+3 induction and 2+5 re-induction chemotherapy.	73	1034	2302	16009	501	859	3291
AML870	D0	Bone marrow	M	32	89 %	ZRSR2 NM_005089 c.1147C>G p.P383A (99.6%, VUS)	"46,XY,t(9;11)(p21;q23)[8].nuc ish(MLLx2)(5' MLL sep 3'MLLx1)[91/100]"	MLL-X	Newly diagnosed AML with recurrent genetic abnormalities, pre-treatment.	345	1004	2586	22163	501	970	2883
AML870	D14	Bone marrow	M	32	1 %	Not performed	Not performed	NA	Ablated, post-induction chemotherapy.	96	1044	2149	8929	501	786	2888
AML997	D0	Bone marrow	M	62	16 %	DNMT3A NM_175629 c.2645G>A p.R882H (43%) /// NPM1 NM_002520 c.859_860insTCTG p.W288fs*>9 (46%) /// CEBPA NM_004364 c.138insT p.A47fs (48%) /// FLT3-ITD (exon 14 ITD)	46,XY	NA	Newly diagnosed AML with monocytic differentiation.	83	1523	4255	35167	501	896	3747
AML997	D35	Bone marrow	M	62	1 %	Not performed	46,XY[20]	NA	Morphologic remission, post-induction chemotherapy.	187	1387	4261	21998	500	886	2995
AML329	D0	Bone marrow	F	73	37 %	NPM1 NM_002520 c.859_860insTCTG p.W288fs*>9 (49.3%) /// NOTCH1 NM_017617 c.5273G>A p.R1758H (67.9%, VUS) /// SMC3 NM_005445 c.3449A>G p.D1150G (45.1%, VUS) /// FLT3-ITD NM_004119 c.1800_1800insCTACGTTGATTTCAGAGAATATGA	46,XX[20]	NA	Newly diagnosed AML with monocytic differentiation, pre-treatment.	525	1005	3444	27174	501	1142	4679
AML329	D20	Bone marrow	F	73	<1%	Unknown	Unknown	NA	Post 7+3 induction chemotherapy, ablated marrow.	953	1000	3394	38276	500	1169	5859
AML329	D37	Bone marrow	F	73	3 %	Unknown	Unknown	NA	Remission.	224	1041	4222	31916	500	1135	4530
AML420B	D0	Bone marrow	M	58	29 %	IDH2 NM_002168 c.419G>A p.R140Q (23.2%) /// TP53 NM_000546 c.818G>T p.R273L (16.0%) /// SH2B3 NM_005475 c.1655A>G p.D552G (55.7%, VUS)	46,XY,add(1)(p36.1)[3]/46,XY[17]	NA	Newly diagnosed AML, pre-treatment. Possible plasma cell neoplasm in the background.	485	1000	2565	30241	501	973	5294
AML420B	D14	Bone marrow	M	58	<5%	Unknown	Unknown	NA	Post 7+3 induction chemotherapy.	1282	1000	2268	14863	501	949	3360
AML420B	D35	Bone marrow	M	58	1 %	Unknown	45,X,-Y,add(1)(p36.1)[1]/46,XY[19]	NA		743	1000	2303	16260	501	1026	3962
AML556	D0	Bone marrow	M	70	79 %	DNMT3A NM_175629 c.2644C>T p.R882C (43.5%) /// NPM1 NM_002520 c.859_860insTCTG p.W288fs*>9 (35.8%) /// NRAS NM_002524 c.183A>T p.Q61H (43.8%) /// NRAS NM_002524 c.35G>A p.G12D (3.8%) /// TET2 NM_001127208 c.3176C>G p.S1059* (37.0%) /// TET2 NM_001127208 c.5412_5413insA p.L1804fs* (34.4%) /// ATM NM_000051 c.6067G>A p.G2023R (51.9%, VUS)	46,XY	NA	Newly diagnosed AML with myelomonocytic differentiation, pre-treatment. Also diagnosed with smoldering myeloma at the same time.	2328	1002	2956	35998	503	1145	5475
AML556	D15	Bone marrow	M	70	0 %	Not performed	Not performed	NA	Ablated, post-induction chemotherapy.	1203	1001	2038	23484	500	827	4700
AML556	D31	Bone marrow	M	70	4 %	Not performed	46,XY[20]	NA	Morphologic remission, post-induction chemotherapy.	1451	1003	3241	21859	501	1115	4259
AML328	D0	Bone marrow	F	74	55 %	DNMT3A NM_175629 c.1910T>A p.L637Q (43.9%) /// TP53 NM_000546 c.431A>C p.Q144P (38.7%, VUS) /// TP53 NM_000546 c.455C>G p.P152R (51.5%) /// FLT3-ITD NM_004119 c.1749_1752delCTCCinsAGGTCAG p.584_585delSinGQ	45,XX,ider(3)(q10)inv(3)(q21q26.2),add(5)(q13),-7,add(9)?dup(q13q22)[19]/46,XX[1].ish ider(3)(RP11-669C7/RP11-637O11 sep,RP11-82C9,RP11-362K14+)x2[5]	NA	Newly diagnosed AML, pre-treatment.	1094	1005	2702	12755	501	1136	3784
AML328	D29	Bone marrow	F	74	20 %	DNMT3A NM_175629 c.1910T>A p.L637Q (28.1%) /// TP53 NM_000546 c.431A>C p.Q144P (44.0%, VUS) /// TP53 NM_000546 c.455C>G p.P152R (20.6%) /// FLT3-ITD NM_004119 c.1749_1752delCTCCinsAGGTCAG p.584_585delSinGQ (9.5%)	45,XX,ider(3)(q10)inv(3)(q21q26.2),add(5)(q13),-7,add(9)?dup(q13q22)[7]/45,idem,add(16)(q13)[cp3]	NA	Azacitidine + venetoclax, C1D27.	1880	1000	3016	23384	501	1313	5207
AML328	D113	Bone marrow	F	74	15 %	DNMT3A NM_175629 c.1910T>A p.L637Q (26.7%) /// TP53 NM_000546 c.431A>C p.Q144P (34.6%, VUS) /// TP53 NM_000546 c.455C>G p.P152R (11.3%) /// FLT3-ITD NM_004119 c.1749_1752delCTCCinsAGGTCAG p.584_585delSinGQ (3.4%)	45,XX,ider(3)(q10)inv(3)(q21q26.2),add(5)(q13),-7,dup(9)(q13q22)[1]/46,XX[1].nuc ish(D5S723/D5S721x2,EGR1x1)[5/100]	NA	Azacitidine + venetoclax, C4D23.	2029	1000	2231	26009	500	869	4820
AML328	D171	Bone marrow	F	74	30 %	Unknown	"45~46,XX,ider(3)(q10)inv(3)(q21q26.2),add(5)(q13),-7,add(9)?dup(9)(q13q22),add(17)(p11.2)[4],+mar[5][cp13]/43~44,idem,add(3)(q12)[2],der(9)t(9;9)(p22;q13),der(15;16)(q10,q10),-17,del(18)(q?21)[2],+mar[2][cp7]"	NA	Azacitidine + venetoclax, C6D17.	1402	1000	1974	20053	500	852	4467
AML707B	D0	Bone marrow	M	26	76 %	BRCC3 NM_024332 c.686_687insTGATGTCGCG p.L229fs* (77.0%) /// KIT NM_000222 c.2468A>G p.Y823C (32.8%) /// RAD21 NM006265 c.1058_1058insCC p.L353fs* (39.7%)	"45,X,-Y,t(8;21)(q22;q22)[10]/45,idem,t(2;5)(p21;q31)[9]/46,XY[1]"	RUNX1-RUNX1T1	Newly diagnosed AML, pre-treatment.	1586	1000	3137	21135	500	1192	4583
AML707B	D18	Bone marrow	M	26	6 %	Unknown	Unknown	NA	Day 17 post 7+3 induction chemotherapy.	1673	1000	2056	29492	500	829	6074
AML707B	D41	Bone marrow	M	26	4 %	None Detected	46,XY[20]	NA	Day 40 post 7+3 induction chemotherapy.	387	1006	2513	16365	500	997	3772
AML707B	D97	Bone marrow	M	26	4 %	Unknown	46,XY[20]	NA	Day 38 post high-dose Ara-C consolidation (HIDAC), C1D38.	84	1026	2498	17715	502	935	4165
AML707B	D113	Bone marrow	M	26	1 %	Unknown	Unknown	NA	Day 54 post HIDAC, C1D54.	708	1001	3125	53511	500	1106	6444
OCI-AML3	NA	Cell line	M	57	NA	BCORL1 NM_021946 c.3714_3715insA p.G1238fs* (18.1%) /// DNMT3A NM_175629 c.2644C>T p.R882C (54.4%) /// NPM1 NM_002520 c.859_860insTCTG p.W288fs*>9 (49.8%) /// NRAS NM_002524 c.182A>T p.Q61L (100.0%) /// RAD21 NM_006265 c.19_19insT p.F6fs* (6.7%) /// SMC3 NM_005445 c.864_882delAGAACAGCTTAGTGCTGAAinsGAAC p.289_294delEQLSAEinsKN (20.1%) /// ATM NM_000051 c.2119T>C p.S707P (48.4%, VUS) /// SETD2 NM_014159 c.5666T>C p.M1889T (44.2%, VUS)	"Hyperdiploid karyotype - 48(45-50)<2n>X/XY, +1, +5, +8, der(1)t(1;18)(p11;q11), i(5p), del(13)(q13q21), dup(17)(q21q25) - sideline with r(Y)x1-2 - hemizygous for RB1"	NA		1178	1002	4037	32048	501	1654	5959
MUTZ3	NA	Cell line	M	29	NA	SF3B1 NM_012433 c.1998G>T p.K666N (45.4%) /// KRAS NM_004985 c.32_32insGAG p.G10_A11insG (24.2%) /// ASXL1 NM_015338 c.3306G>T p.E1102D (53.4%, VUS) /// GATA2 NM_032638 c.919C>T p.R307W (53.4%, VUS) /// IKZF1 NM_006060 c.476A>G p.N159S (52.6%, VUS)	"Near-diploid karyotype with 6% tetraploidy - 46(44-48)<2n>XY, t(1;3)(q43;q13)inv(3)(q21q26), t(2;7)(q36;q36)inv(7)(p15q36), t(12;22)(p13;q12) - carries t(12;22) recurrent in AML M4 - also carries masked inv(3) associated with abnormal megakaryocytopoiesis"	NA		1502	1012	6303	45164	500	1882	6018